Local clinical trial approval times in the UK

被引:0
|
作者
Chester P. [1 ,4 ]
Aalam S. [2 ]
Cooper P. [2 ]
Risley C. [2 ]
Dornhorst A. [3 ]
机构
[1] Oxford Centre for Diabetes Endocrinology and Metabolism, Churchill Hospital, Oxford
[2] Kendle UK Ltd., Crowthorne
[3] Hammersmith Hospital, London
[4] Oxford Centre for Diabetes Endocrinology and Metabolism, Churchill Hospital, Oxford
关键词
National Health Service; Insulin Detemir; Primary Care Trust; Investigational Medicinal Product; National Health Service Hospital;
D O I
10.2165/00124363-200620050-00006
中图分类号
学科分类号
摘要
Aim: This study aimed to evaluate the impact of local approval times on the schedule of a large multicentre study in the UK. Method: We reviewed the approval times of 178 applications that were made to the UK National Health Services Trusts (across 159 hospitals and 19 primary care trusts). Results: The mean time for approval was 82 days; more than half the submissions (94; 53%) took longer than 60 days for a decision. The reason for taking over 60 days varied but review of the trial documentation revealed that delays occurred in the Hospital R&D Office for 25 (14%) submissions, at the hospital or primary care trust level for 14 (8%) submissions, while the investigator was responsible for 23 (13%) applications taking longer than 60 days. Conclusion: Local submissions are a source of delayed start up in many centres participating in clinical trials; however, reasons for delay are not consistent across the applications and cannot be attributed to one specific part of the local approval process. © 2006 Adis Data Information BV. All rights reserved.
引用
收藏
页码:317 / 320
页数:3
相关论文
共 50 条
  • [31] FDA to slash drug approval times
    不详
    [J]. CHEMISTRY & INDUSTRY, 2003, (13) : 5 - 5
  • [32] Approval times and the safety of new pharmaceuticals
    Rudholm N.
    [J]. The European Journal of Health Economics, 2004, 5 (4) : 345 - 350
  • [33] Drug approval times - The author responds
    Rawson, NSB
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2000, 162 (13) : 1804 - 1804
  • [34] UK approval for social anxiety drug
    不详
    [J]. CHEMISTRY & INDUSTRY, 1998, (20) : 833 - 833
  • [35] CLINICAL TRIAL OF XYLOCAINE IN LOCAL ANAESTHESIA
    CARNEGIE, DM
    HEWER, AJH
    [J]. LANCET, 1950, 259 (JUL1): : 12 - 14
  • [36] Assessment and approval of drugs to be reviewed in the UK
    Geddes, Linda
    [J]. LANCET ONCOLOGY, 2014, 15 (12): : E530 - E530
  • [37] Fungicide - Amistar wins UK approval
    不详
    [J]. EUROPEAN CHEMICAL NEWS, 1997, 67 (1763): : 23 - 23
  • [38] Clinical research and trial registries: the times they are a-changin
    Hadzic, Admir
    Vandepitte, Catherine
    Knezevic, Nebojsa Nick
    Mesotten, Dieter
    Kuroda, Maxine M.
    Van Boxstael, Sam
    Bellemans, Johan
    Van de Velde, Marc
    Fivez, Tom
    Corten, Kristoff
    [J]. REGIONAL ANESTHESIA AND PAIN MEDICINE, 2020, 45 (10) : 844 - 846
  • [39] THE IMPACT OF THE CLINICAL-TRIAL EXEMPTION SCHEME ON CLINICAL DEVELOPMENT IN THE UK
    TURNBULL, AG
    LIS, Y
    PARRISH, J
    WALKER, SR
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 29 (05) : P616 - P617
  • [40] TREATMENT OF PARKINSONISM WITH UK 738 - A CLINICAL-TRIAL
    SUMNER, D
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 1962, 119 (06): : 534 - &